slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 41,911-41,940
Pages 10,126
Rows per page 30
Component
41,911-41,940 of 303,780
37
The slide outlines a standard oncology clinical trial design (Phase 1/2) with a transition point at RP2D (Recommended Phase 2 Dose).Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
38
Includes a biological pathway diagram and a honeycomb diagram for indications.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
39
The slide uses a three-column layout to define the target product profile (TPP) requirements for a CDK7 inhibitor.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
40
The table uses a color-coded heatmap (green/yellow/red) to indicate performance against criteria.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
41
Data source: Besnard et al, AACR (2022).Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
42
The slide uses a small multiples approach to show dose-response curves across 10 patient samples, then aggregates them into two groups to highlight differential sensitivity.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
43
The right chart is a waterfall plot showing drug response scores across 53 patient samples, categorized by tumor type and responder status.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
44
The slide shows a hierarchical clustering heatmap of gene expression alongside bar charts comparing experimental vs predicted tDRS values for 30 sample patients.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
46
TPP stands for Target Product Profile.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
47
The slide uses a traffic-light color coding system (green/yellow/red) to visualize performance metrics.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
48
The slide uses a process-flow layout to describe the company's proprietary drug discovery methodology.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
50
Exscientia | Investor Presentation Deck | 73 slidesExscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
51
Includes two distinct biological diagrams/illustrations and citations for scientific literature.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
52
The slide uses a three-column layout to define the technical requirements for the drug candidate.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
53
The slide uses a color-coded heatmap (green/yellow/red/grey) to visualize performance against target product profile (TPP) criteria.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
54
The slide uses a linear process flow to describe a drug discovery pipeline.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
55
The chart illustrates a Pareto front analysis in drug discovery, highlighting the selection of compounds that are not necessarily 'optimal' by standard metrics but provide high information value.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
56
Includes statistical significance markers (*) and safety observation regarding body weight.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
57
The slide uses two distinct chart types (dot plot and line chart) to contrast the safety profiles of reversible vs irreversible LSD1 inhibitors.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
58
The chart shows tumour volume over time for various dosing regimens, with statistical significance indicated by ****.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
59
Exscientia | Investor Presentation Deck | 73 slidesExscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
60
Includes a definition for MIDD at the bottom left.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
62
Exscientia | Investor Presentation Deck | 73 slidesExscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
63
Exscientia | Investor Presentation Deck | 73 slidesExscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
64
Exscientia | Investor Presentation Deck | 73 slidesExscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
65
Exscientia | Investor Presentation Deck | 73 slidesExscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
66
The slide uses a color-coded matrix to highlight that competitors fail on UGT1A1 inhibition, while EXS73565 succeeds.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
67
The slide outlines a multi-stage pipeline: Initiate, Analyse, Evolve, 2D Models, 3D Models, and Active Learning.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
68
The slide highlights the technical methodology behind a specific drug candidate ('565) using molecular dynamics.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits
69
The chart shows dose-dependent tumour volume reduction over time compared to vehicle control.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction2 hits